Vertex Pharmaceuticals Incorporated (VRTX)
| Market Cap | 124.35B |
| Revenue (ttm) | 11.02B |
| Net Income (ttm) | -535.60M |
| Shares Out | 256.79M |
| EPS (ttm) | -2.08 |
| PE Ratio | n/a |
| Forward PE | 26.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,315,240 |
| Open | 481.36 |
| Previous Close | 480.33 |
| Day's Range | 479.85 - 487.38 |
| 52-Week Range | 377.85 - 519.88 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 505.61 (+4.41%) |
| Earnings Date | Feb 10, 2025 |
About VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is $505.61, which is an increase of 4.41% from the latest price.
News
Vertex to Participate in Upcoming March Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Stuart Arbuckle, Executive Vice President a...
High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models
Deshawn "DJ" Chow is one of just over 100 sickle cell patients who have undergone treatment with new gene therapies. CVS Health CEO David Joyner said private insurers and employer-sponsored health pla...
Calls of the Day: Charles Schwab, Vertex Pharma and Transocean
The Investment Committee debate the latest Calls of the Day.
Vertex Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results
Vertex Pharmaceuticals Incorporated VRTX reported mixed results for its fourth quarter on Monday.
Vertex Pharmaceuticals Incorporated (VRTX) Q4 2024 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2024 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Reshma Kewa...
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts' expectations.
Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its cystic fibrosis drugs and early contributions from a newly approved non-opi...
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided its...
Vertex Q4 Earnings On Deck: Will This Biotech Heavyweight Keep Its Edge?
Vertex Pharmaceuticals Inc VRTX is set to report fourth quarter earnings after the market closes Monday. Biotech investors are bracing for impact.
Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings
Vertex Pharmaceuticals Incorporated VRTX will release its fourth-quarter financial results, after the closing bell, on Monday, Feb. 10, 2025.
Final Trades: Energy Transfer, Vertex Pharma, UnitedHealth and Axon Enterprise
The Investment Committee give you their top stocks to watch for the second half.
Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential. Phase 2 ...
Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine
Expectation is a decline in Vertex's earnings, but double-digit revenue growth should continue with the newly approved non-opioid drug JOURNAVX and CF franchise expansion. JOURNAVX, the first non-opio...
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
JOURNAVX, a non-opioid analgesic, shows significant promise in treating pain with a superior safety profile, addressing a critical unmet need compared to opioids with FDA approval just announced. Vert...
FDA approves a new painkiller for the first time in decades
Vertex Pharmaceuticals' non-opioid painkiller comes without the potential risk of addiction. Transcript: Conway Gittens: Wall Street heads into the weekend with modest strength - and that's no small f...
Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
Shares of Vertex Pharmaceuticals (VRTX) surged Friday, a day after the drugmaker reported federal regulators have approved its non-opioid painkiller, the first such drug to head to market in two decad...
Vertex Pharmaceuticals CEO on non-opioid painkiller: It's safe, effective and non-addictive
CNBC's Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the FDA's approval of the company's non-opioid painkiller pill Journavx, a new ...
What's Happening With VRTX Stock?
Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can potentia...
Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.
FDA approves Vertex's non-opioid painkiller - first new kind of pain medicine in decades
CNBC's Becky Quick reports on the latest news.
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday's market open after the Food and Drug Administration approved the company's non-opioid pain treatment.
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene...
FDA Approves Non-Opioid Painkiller With No Addiction Risk
The Food and Drug Administration approved Vertex Pharmaceuticals' “Journavx” on Thursday, greenlighting the non-opioid painkiller for treating moderate to severe pain in what the FDA considered the st...
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, ...
US FDA approves Vertex's non-opioid painkiller
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator said on Thursday, offering an alternative to addictive opioid painkillers that...